Novo weathering the storm in Russia; Mylan and Gilead expand hep C licensing pact; NICE OKs Soliris;

> Novo Nordisk ($NVO) says it intends to stay in Russia for the "long haul" despite the country's ongoing economic downturn. Report

> Mylan ($MYL) is expanding its hep C licensing agreement with Gilead ($GILD) to include an investigational pan-genotypic prospect. Release

> The U.K.'s cost-effectiveness gatekeeper has approved Alexion's ($ALXN) Soliris in final guidance, making it the first med to pass through the watchdog's new assessment system for highly specialized technologies. Report

> GlaxoSmithKline ($GSK) has rolled out new respiratory treatments Arnuity Ellipta for asthma and Incruse Ellipta for COPD in the U.S. Release

> Purdue Pharma has launched Hysingla ER, a once-daily opioid with abuse-deterrent properties. Release

And Finally... Procter & Gamble's ($PG) ZzzQuil's Twitter feed came under fire last week for a tweet critics called sexist. More

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.